Company news
Pyc Therapeutics Limited (ASX:PYC) news
Pyc Therapeutics Limited news releases on 6ix. Latest, Sep 4, 2026: S&P DJI Announces September 2026 Quarterly Rebalance
Press releases & updates
S&P DJI Announces September 2026 Quarterly Rebalance
September 4, 2026
PKD - Safety Committee Approves Dose Escalation
July 21, 2026
ADOA Program Update
July 20, 2026
PKD - Initiation of Multiple Dose Clinical Trial
May 6, 2026
Presentation of Ophthalmology Clinical Trial Data at ARVO
May 3, 2026
ADOA Program - SRC Approve Progression to Multi-Dose Study
April 15, 2026
Completion of Retail Entitlement Offer
March 3, 2026
PKD Clinical Trial - Approval to Escalate Dosing
February 26, 2026
Half Yearly Report and Accounts
February 23, 2026
Retail Offer Booklet
February 8, 2026
Completion of Placement and Institutional Entitlement Offer
February 3, 2026
PYC Raising up to $653m to Deliver Human Efficacy Data
February 1, 2026
PYC Capital Raising Presentation
February 1, 2026
Trading Halt
February 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 22, 2026
PKD Clinical Trial - Safety Outcomes in Part A
December 18, 2025
Sustained Vision Improvement in RP11 Patients
November 13, 2025
ADOA Program Initiation of Global Repeat Dose Study
October 20, 2025
PMS Program Data Supports Progression to Human Trials
October 12, 2025
ADOA Program Progressing to Multiple Dose Study
October 8, 2025
Board and Management Changes
September 21, 2025
Correction to Trading Halt Request
September 19, 2025
Change of Managing Director
September 16, 2025
ADOA Program - Presentation of Clinical Data at NOSA 2025
September 4, 2025
PKD Program - Presentation of Safety Data at ANZSN
August 28, 2025
Appendix 4E
August 28, 2025
Approval to Escalate Dosing in Kidney Disease Clinical Trial
August 7, 2025
Approval to Progress Kidney Disease Trial to Next Stage
July 6, 2025
Fourth Drug Program Progressing to Human Trials
June 26, 2025
FDA Alignment on Registrational Trial Design RP11 Program
June 22, 2025
SRC Approves Dose Escalation in ADOA Clinical Trial
June 10, 2025
Approval to Escalate Dosing in Kidney Disease Trial
May 25, 2025
Presentation of Clinical Proof of Concept in Lead Program
April 27, 2025
Completion of Entitlement Offer
April 16, 2025
First Subject Dosed in PKD Clinical Trial
April 9, 2025
Placement of Shortfall
April 9, 2025
Retail Entitlement Offer Booklet
February 24, 2025
Completion of Institutional Entitlement Offer
February 18, 2025
PYC Equity Raising Presentation
February 16, 2025
PYC Equity Raising to Raise up to $146 Million
February 16, 2025
Approval to Commence Human Trials in Kidney Program
February 9, 2025
ADOA Safety Review Committee Approves Dose Escalation
January 30, 2025
US FDA Grants Rare Pediatric Disease Designation to VP-001
January 19, 2025
PYC Nominates Fourth Clinical Drug Candidate in PMS Program
December 15, 2024
PYC to Progress Kidney Drug Candidate Into Human Trials
November 26, 2024
Consolidation/Split - PYC
November 11, 2024
RP11 SRC Approves Dose Escalation to Final Patient Cohort
November 4, 2024
First ADOA Patient Dosed in Clinical Trial
October 31, 2024
Interim Update on Progress in RP11 Repeat Dose Trials
October 21, 2024
US FDA Grants Orphan Drug Designation to PYC Drug Candidate
October 20, 2024